Drug recall · May 22, 2024
Cefdinir for Oral Suspension USP 250 mg/5 mL recall
Why: Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Cefdinir for Oral Suspension USP 250 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, United States, Manufactured by: Lupin Limited, Mandideep 462 046, India, NDC 68180-723-04
- Lots / codes
Lot # F305442, Exp 8/30/2025
- Quantity
- 17,070 bottles
- Company
- Lupin Pharmaceuticals Inc., Baltimore, MD
- Distribution
- USA nationwide
- Initiated
- April 24, 2024 · Voluntary: Firm initiated
- Classified
- May 14, 2024
- Reported
- May 22, 2024
- Ended
- April 29, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Cefdinir
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.